Neuroscience

Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s

Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile…

1 year ago

BrainsWay Announces Presentation of Two Deep TMS™ Posters at Upcoming World Congress of Psychiatry

Preliminary Research on Late Life Depression and Accelerated Depression Treatment Protocol will be FeaturedBURLINGTON, Mass. and JERUSALEM, Sept. 27, 2023…

1 year ago

Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral…

1 year ago

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed…

1 year ago

Brain Canada’s flagship program awards $2.8 million for brain research

Brain Canada’s Future Leaders in Canadian Brain Research program to support 28 early-career researchers this year The 2022 Future Leaders…

1 year ago

Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology

New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British…

1 year ago

Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100

Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical researchDURHAM, N.C., Sept. 20, 2023…

1 year ago

Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,…

1 year ago

Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity

Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and…

1 year ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Purchases All 5,323,451 Shares Validly Tendered at $0.70 per SharePALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) --…

1 year ago